Intrabodies against the EVH1 domain of Wiskott-Aldrich syndrome protein inhibit T cell receptor signaling in transgenic mice T cells

FEBS Journal

Volumn 272, Issue 23, 2005, Pages 6131-6144

  Sato, Mitsuru ^a   Iwaya, Ryo ^a,b   Ogihara, Kazumasa ^a   Sawahata, Ryoko ^a   Kitani, Hiroshi ^a   Chiba, Joe ^b   Kurosawa, Yoshikazu ^c   Sekikawa, Kenji ^a,d  

^a NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Cytosolic protein; Functional knockdown; Intrabody; T cell receptor signaling; Wiskott Aldrich syndrome protein (WASP)

Indexed keywords

ENABLED VASODILATOR STIMULATED PHOSPHOPROTEIN HOMOLOGY 1; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2; PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; WISKOTT ALDRICH SYNDROME PROTEIN;

ACTIN POLYMERIZATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ARTICLE; CAPPING PHENOMENON; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOL; ENDOPLASMIC RETICULUM; GENE OVEREXPRESSION; HYBRIDOMA CELL CULTURE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BASE SEQUENCE; CELL PROLIFERATION; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-2; INTRACELLULAR SPACE; LYMPHOID TISSUE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; WISKOTT-ALDRICH SYNDROME PROTEIN;

ANIMALIA; MUS MUSCULUS;

EID: 28244456225     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.05011.x     Document Type: Article

References (47)

1. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS & Whitlow M (1988) Single-chain antigen-binding proteins. Science 242, 423-426.
2. Huston S, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R & Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85, 5879-5883.
3. Barbas CF III, Kang AS, Lerner RA & Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 88, 7978-7982.
4. Zhu H, Biligin M & Snyder M (2003) Proteomics. Annu Rev Biochem 72, 783-812.
5. Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20, 446-448.
6. Marasco WA, Haseltine WA & Chen SY (1993) Design, intracellular expression, and activity of a human antihuman immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90, 7889-7893.
7. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE & Barbas CF III (2000) Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 97, 805-810.
8. Richardson JH, Sodroski JG, Waldmann TA & Marasco WA (1995) Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA 92, 3137-3141.
9. Mhashilkar AM, Doebis C, Seifert M, Busch A, Zani C, Soo Hoo J, Nagy M, Ritter T, Volk HD & Marasco WA (2002) Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther 9, 307-319.
10. Tanaka T & Rabbitts TH (2003) Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J 22, 1025-1035.
11. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B & Bracco L (1999) Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18, 551-557.
12. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, et al. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD 21): a phase I trial. Clin Cancer Res 6, 3081-3087.
13. Worn A & Pluckthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305, 989-1010.
14. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA & Wedgwood RJ (1980) The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 55, 243-252.
15. Remold-O'Donnell E, Rosen FS & Kenney DM (1996) Defects in Wiskott-Aldrich syndrome blood cells. Blood 87, 2621-2631.
16. Molina IJ, Sancho J, Terhorst C, Rosen FS & Remold-O'Donnell E (1993) T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol 151, 4383-4390.
17. Snapper SB, Rosen FS, Mizoguchi E, Cohen P, Khan W, Liu CH, Hagemann TL, Kwan SP, Ferrini R, Davidson L, et al. (1998) Wiskott-Aldrich syndrome protein × deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9, 81-91.
18. Zhang J, Shehabeldin A, da Cruz LA, Butler J, Somani AK, McGavin M, Kozieradzki I, dos Santos AO, Nagy A, Grinstein S, et al. (1999) Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein × deficient lymphocytes. J Exp Med 190, 1329-1342.
19. Symons M, Derry JM, Karlak B, Jiang S, Lemahieu V, Mccormick F, Francke U & Abo A (1996) Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 84, 723-734.
20. Rivero-Lezcano OM, Marcilla A, Sameshima JH & Robbins KC (1995) Wiskott-Aldrich syndrome protein physically associates with Nek through Src homology 3 domains. Mol Cell Biol 15, 5725-5731.
21. She HY, Rockow S, Tang J, Nishimura R, Skolnik EY, Chen M, Margolis B & Li W (1997) Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cells. Mol Biol Cell 8, 1709-1721.
22. Banin S, Truong O, Katz DR, Waterfield MD, Brickell PM & Gout I (1996) Wiskott-Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases. Curr Biol 6, 981-988.
23. Blanchoin L, Amann KJ, Higgs HN, Marchand JB, Kaiser DA & Pollard TD (2000) Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins. Nature 404, 1007-1011.
24. Sato M, Tsuji NM, Gotoh H, Yamashita K, Hashimoto K, Tadotsu N, Yamanaka H, Sekikawa K & Hashimoto Y (2001) Overexpression of the Wiskott-Aldrich syndrome protein N-terminal domain in transgenic mice inhibits T cell proliferative responses via TCR signaling without affecting cytoskeletal rearrangements. J Immunol 167, 4701-4709.
25. Tsai B, YeY & Rapoport TA (2002) Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 3, 246-255.
26. Hershko A, Ciechanover A & Varshavsky A (2000) The ubiquitin system. Nat Med 6, 1037-1081.
27. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2, 169-178.
28. Coux O, Tanaka K & Goldberg AL (1996) Structure and function of the 20S and 26S proteasomes. Annu Rev Biochem 65, 801-847.
29. Ellgaard L & Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4, 181-191.
30. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Heiland DG & Marasco WA (1995) Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 14, 1542-1551.
31. Zhu Q, Zeng C, Huhalov A, Yao J, Turi TG, Danley D, Hynes T, Cong Y, DiMattia D, Kennedy S, et al. (1999) Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods 231, 207-222.
32. Munro S & Pelham HR (1986) An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46, 291-300.
33. Flynn GC, Pohl J, Flocco MT & Rothman JE (1991) Peptide-binding specificity of the molecular chaperone BiP. Nature 353, 726-730.
34. Lencer WI & Tsai B (2003) The intracellular voyage of cholera toxin: going retro. Trends Biochem Sci 28, 639-645.
35. Breitschopf K, Bengal E, Ziv T, Admon A & Ciechanover A (1998) A novel site for ubiqitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. EMBO J 17, 5964-5973.
36. Dustin ML & Cooper JA (2000) The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 1, 23-29.
37. Krawczyk C & Penninger JM (2001) Molecular controls of antigen receptor clustering and autoimmunity. Trends Cell Blol 11, 212-220.
38. Cannon JL & Burkhardt JK (2004) Differential roles for Wiskott-Aldrich syndrome protein in immune synapse formation and IL-2 production. J Immunol 173, 1658-1662.
39. Silvin C, Belisle B & Abo A (2001) A role for Wiskott-Aldrich syndrome protein in T-cell receptor-mediated transcriptional activation independent of actin polymerization. J Biol Chem 276, 21450-21457.
40. Fischer KD, Kong YY, Nishina H, Tedford K, Marengere LE, Kozieradzki I, Sasaki T, Starr M, Chan G, Gardener S, et al. (1998) Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr Biol 8, 554-562.
41. Holsinger LJ, Graef IA, Swat W, Chi T, Bautista DM, Davidson L, Lewis RS, Alt FW & Crabtree GR (1998) Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr Biol 8, 563-572.
42. Wu J, Katzav S & Weiss A (1995) A functional T-cell receptor signaling pathway is required for p95vav activity. Mol Cell Biol 15, 4337-4346.
43. Savoy DN, Billadeau DD & Leibson PJ (2000) WIP, a binding partner for Wiskott-Aldrich syndrome protein, cooperates with Vav in the regulation of T cell activation. J Immunol 164, 2866-2870.
44. Anton IM, de la Funte MA, Sims TN, Freeman S, Ramesh N, Hartwig JH, Dustin ML & Geha RS (2002) WIP deficiency reveals a differential role for WIP and the actin cytoskeleton in T and B cell activation. Immunity 16, 193-204.
45. Niwa H, Yamamura K & Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199.
46. Takemoto Y, Furuta M, Sato M, Kubo M & Hashimoto Y (1999) Isolation and characterization of a novel HS1 SH3 domain binding protein, HS1BP3. Int Immunol 11, 1957-1964.
47. Shimonkevitz R, Kappler J, Marrack P & Grey H (1983) Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 158, 303-316.